- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02287792
18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis (TEPvENDO)
Effect of 18-FDG PET/CT Imaging on Clinical Decision Making During the Acute Phase of Infective Endocarditis: a Multicenter Prospective Impact Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction:
Infective endocarditis (IE) is a rare disease, often difficult to diagnose with a high mortality rate. Extra-cardiac manifestations, which can occur in 30 to 80% of cases, impact the outcome of the disease. Identifying these manifestations may help confirm an uncertain diagnosis and optimize patients' management.
18-FDG PET/CT imaging, widely used for cancer staging, may also detect hyper-metabolic areas related to extracardiac infectious complications of IE. It provides the opportunity to detect all extracardiac IE infectious complications through a single examination. The impact of 18-FDG PET/CT imaging on the management of IE has yet to be completely evaluated.
Hypothesis:
18-FDG PET/CT implementation could result in both shortening of the initial diagnostic work-up of IE and therapeutic optimization.
Primary objective:
To evaluate the impact of 18-FDG PET/CT on patients' management, as measured by changes in IE therapeutic plans.
Secondary objectives:
- To evaluate the impact of 18-FDG PET/CT on the Duke-Li criteria for IE diagnosis
- To evaluate the performance of 18-FDG PET/CT in detecting valve damages and extracardiac complications induced by the IE
- To evaluate whether 18-FDG PET/CT may help identify the infection's portal of entry
- To evaluate whether the detection of extracardiac complications by FDG PET/CT is associated with the 6-months survival rate
- To identify clinical and biological determinants of extracardiac IE localizations and prognosis
- To determine the inter-reader interpretation of the18-FDG PET/CT results and the reproducibility in preparation and acquisition method
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75018
- Bichat Claude Bernard Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged ≥ 18 years
- Presenting IE "Duke-Li definite - Duke-Li possible" or strong suspicion of IE "Duke-Li not definite or possible, with initiation of IE antibiotic therapy".
- Transthoracic or transesophageal ultrasound performed.
- A stable clinical condition which does not require immediate surgery or contraindicate patient mobilization
- Absence of cardiac surgery for the current IE episode
- Covered by the French health insurance system
- Having given and signed the written study informed consent to the study.
Exclusion Criteria:
- Patient having already had a 18-FDG PET/CT in the current episode
- Contraindication to perform a 18-FDG PET/CT
- Early prosthetic valve IE (cardiac surgery within last 2 months)
- Inability to understand the information form
- Pregnant or lactating woman.
- Cardiac surgery between inclusion and 18-FDG PET/CT
- Participation to any clinical trial including 18-FDG PET/CT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18-FDG PET/CT scan
All patients will undergo a whole body PET/CT scan
|
Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with a change in IE therapeutic plan
Time Frame: 7 days
|
at least one modification in antimicrobial or anticoagulant therapy (types, route, dose, number, duration, indication…) or any modification of surgery (type, timing, indications…)
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with Duke-Li classification modifications
Time Frame: 6 months
|
Proportion of patients with change in diagnostic classification of IE (definite, possible, excluded) according to the Duke-Li classification
|
6 months
|
Performances of 18-FDG PET/CT in detection of IE localization as compared to other usual procedures
Time Frame: 6 months
|
1/ in detecting valve damages and extracardiac complications and 2/ in identify the portal of entry of IE
|
6 months
|
6-month mortality rate
Time Frame: 6 months
|
number of dead patients 6 months after inclusion
|
6 months
|
Determinants of change in therapeutic plan as defined in primary outcome
Time Frame: 6 months
|
Clinical and biological determinants of therapeutic changes
|
6 months
|
18-FDG PET/CT inter-reader reproducibility
Time Frame: 6 months
|
questionnaire
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xavier Duval, Professor, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AOM13549
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infective Endocarditis
-
Emil Loldrup FosbolHvidovre University Hospital; Bispebjerg Hospital; Amager Hospital; Herlev and... and other collaboratorsRecruitingEndocarditis InfectiveDenmark, Netherlands, Sweden
-
LysovantWithdrawnEndocarditis Infective | Bacteremia Due to Staphylococcus Aureus | Left Sided Infective Endocarditis (Disorder) | Right Sided Infective Endocarditis (Disorder)United States
-
Fundacion Clinic per a la Recerca BiomédicaNot yet recruitingEndocarditis InfectiveSpain
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEndocarditis InfectiveItaly
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Assistance Publique Hopitaux De MarseilleUnknownInfective Endocarditis (IE)France
-
Region SkaneCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingProsthetic Valve EndocarditisFrance
-
Assiut UniversityRecruitingProsthetic Valve EndocarditisEgypt
-
Montreal Heart InstituteRecruitingInfective Endocarditis | Native Valve EndocarditisCanada
Clinical Trials on 18-FDG PET/CT scan
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruitingThyroid Cancer | Lymph Node Metastases | Positron-Emission TomographyChina
-
Memorial Sloan Kettering Cancer CenterRecruitingLiver MetastasesUnited States
-
University of PennsylvaniaCompleted
-
University of California, Los AngelesCenters for Medicare and Medicaid ServicesCompleted
-
Jules Bordet InstituteCompletedColorectal Cancer Metastatic | Early Response Evaluation | Fdg-PETBelgium
-
University of ArizonaBlue Earth Diagnostics; Banner University Medical CenterCompletedProstate AdenocarcinomaUnited States
-
University of Alabama at BirminghamRecruitingIdiopathic Pulmonary FibrosisUnited States
-
Washington University School of MedicineRecruiting
-
University of PennsylvaniaActive, not recruitingBone Metastases | Estrogen Receptor Positive Breast CancerUnited States